Cargando…
Optimizing maturity and dose of iPSC-derived dopamine progenitor cell therapy for Parkinson’s disease
In pursuit of treating Parkinson’s disease with cell replacement therapy, differentiated induced pluripotent stem cells (iPSC) are an ideal source of midbrain dopaminergic (mDA) cells. We previously established a protocol for differentiating iPSC-derived post-mitotic mDA neurons capable of reversing...
Autores principales: | Hiller, Benjamin M., Marmion, David J., Thompson, Cayla A., Elliott, Nathaniel A., Federoff, Howard, Brundin, Patrik, Mattis, Virginia B., McMahon, Christopher W., Kordower, Jeffrey H. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9023503/ https://www.ncbi.nlm.nih.gov/pubmed/35449132 http://dx.doi.org/10.1038/s41536-022-00221-y |
Ejemplares similares
-
Cryopreservation Maintains Functionality of Human iPSC Dopamine Neurons and Rescues Parkinsonian Phenotypes In Vivo
por: Wakeman, Dustin R., et al.
Publicado: (2017) -
Mitomycin‐C treatment during differentiation of induced pluripotent stem cell‐derived dopamine neurons reduces proliferation without compromising survival or function in vivo
por: Hiller, Benjamin M., et al.
Publicado: (2020) -
Organ-Chips Enhance the Maturation of Human iPSC-Derived Dopamine Neurons
por: Otero, Maria G., et al.
Publicado: (2023) -
Calcium dysregulation combined with mitochondrial failure and electrophysiological maturity converge in Parkinson’s iPSC-dopamine neurons
por: Beccano-Kelly, Dayne A., et al.
Publicado: (2023) -
Inducible Expression of GDNF in Transplanted iPSC-Derived Neural Progenitor Cells
por: Akhtar, Aslam Abbasi, et al.
Publicado: (2018)